Browsing Tag
Zilurgisertib
1 post
Mirum wins Atebrioz FDA approval after $16m Incyte licence in rare FOP market
Mirum Pharmaceuticals has secured FDA approval for Atebrioz in patients aged 12 and older with fibrodysplasia ossificans progressiva, only months after licensing zilurgisertib from Incyte for $16 million upfront plus milestones and royalties.